ArticleClinical research in cardiology : official journal of the German Cardiac Society2013
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Pooled it
- Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Pooled it
- Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis.International urology and nephrology · 2019Pooled it
- Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Trial
- Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure.Disease markers · 2019Trial
- Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Trial
- Intermittent levosimendan treatment in patients with severe congestive heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Trial
- Galectin-3 associates with NF-κB activation and mitochondrial redox-related protein signatures in catecholamine-induced stress cardiomyopathy.Molecular medicine (Cambridge, Mass.) · 2026Article
- The correlation between serum ECM1 and cardiac fibrosis in heart failure patients.BMC cardiovascular disorders · 2025Article
- Predictors of Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction.Current heart failure reports · 2025Review
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Transcoronary study of biomarkers in patients with heart failure: Insights into intracardiac production.ESC heart failure · 2025Article
- Serum Galectin-3 and Risk Stratification in Chronic Heart Failure: A Systematic Review of Mortality Outcomes.Cureus · 2025Review
- Combination Between Biomarkers and Echocardiographic Data for Prediction of Left Ventricular Reverse Remodelling in Cardiac Resynchronization Therapy.Journal of clinical medicine · 2025Article
- Evaluation of Thrombomodulin, Heart-Type Fatty-Acid-Binding Protein, Pentraxin-3 and Galectin-3 Levels in Patients with Myocardial Infarction, with and Without ST Segment Elevation.Journal of clinical medicine · 2025Article
- Heart failure, inflammation and exercise.International journal of biological sciences · 2025Review
- The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.Frontiers in immunology · 2025Review
- Evaluation of Galectin-3 in Dogs with Atrial Fibrillation.Animals : an open access journal from MDPI · 2024Article
- Novel Impact of Colchicine on Interleukin-10 Expression in Acute Myocardial Infarction: An Integrative Approach.Journal of clinical medicine · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGalectin-3 (Gal-3) is a recently discovered marker for myocardial fibrosis and elevated levels are associated with an impaired outcome after short-term follow-up in heart failure (HF) patients. However, whether Gal-3 is related to cardiac remodeling and outcome after long-term follow-up is unknown. Therefore, we determined the utility of Gal-3 as a novel biomarker for left ventricular remodeling and long-term outcome in patients with severe chronic HF. METHODS AND
resultsA total of 240 HF patients with New York Heart Association (NYHA) Class III and IV were included. Patients were followed for 8.7 ± 1 years, had a mean age of 71 ± 0.6 years and 73 % of the study population was male. Circulating levels of NT-proBNP and Gal-3 were measured. Serial echocardiography was performed at baseline and at 3 months. At baseline median left ventricular end-diastolic volume (LVEDV) was 267 mL [interquartile range 232-322]. Patients were divided into three groups according to the change in LVEDV. Patients in whom the LVEDV decreased over time had significant lower levels of Gal-3 at entry compared to patients in whom the LVEDV was stable or increased (14.7 vs. 17.9 vs. 19.0 ng/mL; p = 0.004 for trend), whereas no significant differences were seen in levels of NT-proBNP (p = 0.33). Multivariate linear regression analyses revealed that Gal-3 levels were positively correlated to change in LVEDV (p = 0.007). In addition, Gal-3 was a significant predictor of mortality after long-term follow-up (p = 0.001).
conclusionGal-3 is associated with left ventricular remodeling determined by serial echocardiography and predicts long-term mortality in patients with severe chronic HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.